Curis notifies press release availability on positive emavusertib update

• Curis released updated clinical data for emavusertib in its registrational TakeAim Lymphoma study in primary CNS lymphoma.
• BTK inhibitor-naive PCNSL showed 86% overall response rate across all patients as of July 1, 2026; 100% in evaluable patients.
• BTK inhibitor-experienced PCNSL showed 26% overall response rate across all patients; 33% in evaluable patients.
• TakeAim CLL enrollment guidance for December 2026 data increased to 5-10 patients; 10 patients consented.
• Webcast details posted at https://investors.curis.com/.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220700PR_NEWS_USPR_____NE09816) on July 22, 2026, and is solely responsible for the information contained therein.